Back HIV Prevention Microbicides


CROI 2012: Conference Overview Highlights Biomedical HIV Prevention

HIV prevention was the key theme at Monday's opening press overview of the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), taking place this week in Seattle.alt

Read more:

VOICE HIV Prevention Trial Halts Tenofovir Gel Arm

On November 25 the National Institutes of Health (NIH) and the Microbicide Trials Network (MTN) announced the discontinuation of an arm of the VOICE study that was evaluating a tenofovir vaginal microbicide, due to lack of effectiveness in an interim analysis.alt

Read more:

Tenofovir Microbicide Gel May Prevent Genital Herpes in Addition to HIV Infection

A vaginal gel containing the HIV nucleotide reverse transcriptase inhibitor tenofovir (known as Viread in pill form, also in the Truvada and Atripla coformulations) inhibits replication of herpes simplex virus, researchers reported in the October 4, 2011, issue of Cell Host and Microbes. Tenofovir gel has already been shown to reduce HIV infection by about 40%, and the new findings suggest it may have a dual benefit.alt

Read more:

UC781 Rectal Microbicide Appears Safe and Well-Tolerated

The investigational rectal microbicide gel UC781 produced no adverse events and study participants said they would be likely to use it if found effective at reducing the risk of HIV infection, according to a study described in the September 28, 2011, edition of PLoS Medicine.alt

Read more:

Gene Therapy Microbicide Protects Mice Against HIV

CD4 cells engineered to knock out HIV genes or CCR5 co-receptors blocked viral infection in laboratory cells and humanized mice, suggesting they can be used in a vaginal microbicide to prevent sexual transmission of HIV.

Read more: